Is IQQQ High Income ETF Good to Buy?
The Proshares NASDAQ-100 High Income ETF (IQQQ) is a covered…
Buy
64
DRUG Quote, Financials, Valuation and Earnings
Last price:
$33.00
Seasonality move
:
10.72%
Day range:
$31.35 - $33.11
52-week range:
$0.93 - $79.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.79x
Volume:
26K
Avg. volume:
32.6K
1-year change:
2804.39%
Market cap:
$233.2M
Revenue:
--
EPS (TTM):
-$0.18
Analysts' Opinion
-
Consensus RatingBright Minds Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $92.13, Bright Minds Biosciences has an estimated upside of 180.36% from its current price of $33.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $92.13 representing -- downside risk from its current price of $33.11.
Fair Value
-
According to the consensus of 2 analysts, Bright Minds Biosciences has 180.36% upside to fair value with a price target of $92.13 per share.
DRUG vs. S&P 500
-
Over the past 5 trading days, Bright Minds Biosciences has overperformed the S&P 500 by 1.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bright Minds Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bright Minds Biosciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bright Minds Biosciences reported revenues of --.
Earnings Growth
-
Bright Minds Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bright Minds Biosciences reported earnings per share of $0.01.
Enterprise value:
192.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-105.96x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$9.6M | -$5M | -$2M | -$1.2M | -$1.2M | |
| EBITDA | -$9.6M | -$5M | -$1.9M | -$1.2M | -$1.1M | |
| Diluted EPS | -$3.63 | -$1.31 | -$0.18 | -$0.32 | $0.01 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.7M | $12.1M | $8.4M | $5.2M | $40.6M | |
| Total Assets | $1.7M | $12.1M | $8.5M | $5.2M | $40.7M | |
| Current Liabilities | $74.8K | $384K | $389.1K | $643.9K | $321.6K | |
| Total Liabilities | $74.8K | $384K | $429.3K | $643.9K | $398.3K | |
| Total Equity | $1.6M | $11.7M | $8.1M | $4.5M | $40.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.7M | -$3.8M | -$1.8M | -$603.9K | -$1.1M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $5.6M | $607.8K | $37M | $645K | $37.1M | |
| Free Cash Flow | -$8.7M | -$3.8M | -$1.8M | -$603.9K | -$1.1M | |
DRUG
Sector
Market Cap
$233.2M
$35M
Price % of 52-Week High
--
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
2804.39%
-41.61%
Beta (5-Year)
--
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$30.70
200-day SMA
Buy
Level
$24.50
Bollinger Bands (100)
Sell
Level
32.63 - 40.71
Chaikin Money Flow
Sell
Level
-171.1K
20-day SMA
Buy
Level
$33.10
Relative Strength Index (RSI14)
Sell
Level
49.69
ADX Line
Sell
Level
26.29
Williams %R
Neutral
Level
-45.9103
50-day SMA
Sell
Level
$35.78
MACD (12, 26)
Buy
Level
4.98
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-230.4K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Stock Forecast FAQ
In the current month, DRUG has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DRUG average analyst price target in the past 3 months is $92.13.
-
Where Will Bright Minds Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bright Minds Biosciences share price will rise to $92.13 per share over the next 12 months.
-
What Do Analysts Say About Bright Minds Biosciences?
Analysts are divided on their view about Bright Minds Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bright Minds Biosciences is a Sell and believe this share price will drop from its current level to $92.13.
-
What Is Bright Minds Biosciences's Price Target?
The price target for Bright Minds Biosciences over the next 1-year time period is forecast to be $92.13 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DRUG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bright Minds Biosciences is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DRUG?
You can purchase shares of Bright Minds Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bright Minds Biosciences shares.
-
What Is The Bright Minds Biosciences Share Price Today?
Bright Minds Biosciences was last trading at $33.00 per share. This represents the most recent stock quote for Bright Minds Biosciences. Yesterday, Bright Minds Biosciences closed at $33.11 per share.
-
How To Buy Bright Minds Biosciences Stock Online?
In order to purchase Bright Minds Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Spotify Ever Become Consistently Profitable?
Spotify (NYSE:SPOT) owns more than 30% market share as the most…
Is American Express a Buy, Sell or Hold?
American Express (NYSE:AXP) holds a notable place in Warren Buffett’s…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 20
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 20
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 20
Global Payments [GPN] is down 17.44% over the past day.
